Concordant hypermethylation of intergenic microRNA genes in human hepatocellular carcinoma as new diagnostic and prognostic marker

International Journal of Cancer

Volumn 133, Issue 3, 2013, Pages 660-670

  Anwar, Sumadi Lukman ^a   Albat, Cord ^a   Krech, Till ^a   Hasemeier, Britta ^a   Schipper, Elisa ^a   Schweitzer, Nora ^a   Vogel, Arndt ^a   Kreipe, Hans ^a   Lehmann, Ulrich ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

DNA methylation; epigenetics; hepatocellular carcinoma; liver; microRNA

Indexed keywords

DNA; DNA METHYLTRANSFERASE 1; GENOMIC DNA; MICRORNA; MICRORNA 124; MICRORNA 1247; MICRORNA 129; MICRORNA 596; MICRORNA 9; UNCLASSIFIED DRUG;

ARTICLE; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIVER CELL; LIVER CELL CARCINOMA; LIVER TUMOR; NODULAR HYPERPLASIA; PRIORITY JOURNAL; PYROSEQUENCING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CPG ISLANDS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; MICRORNAS; PROGNOSIS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL;

EID: 84878012746     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28068     Document Type: Article

References (45)

1. Garzon R, Calin GA, Croce CM,. MicroRNAs in Cancer. Annu Rev Med 2009; 60: 167-79.
2. Jansson MD, Lund AH,. MicroRNA and cancer. Mol Oncol 2012; 6: 590-610.
3. Wang XW, Heegaard NH, Orum H,. MicroRNAs in liver disease. Gastroenterology 2012; 142: 1431-43.
4. Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006; 9: 435-43.
5. Kunej T, Godnic I, Ferdin J, et al. Epigenetic regulation of microRNAs in cancer: an integrated review of literature. Mutat Res 2011; 717: 77-84.
6. Kozaki K, Inazawa J,. Tumor-suppressive microRNA silenced by tumor-specific DNA hypermethylation in cancer cells. Cancer Sci 2012; 103: 837-45.
7. Datta J, Kutay H, Nasser MW, et al. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 2008; 68: 5049-58.
8. Furuta M, Kozaki KI, Tanaka S, et al. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010; 31: 766-76.
9. Alpini G, Glaser SS, Zhang JP, et al. Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer. J Hepatol 2011; 55: 1339-45.
10. Kim JK, Noh JH, Jung KH, et al. SIRT7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors mir-125a-5p and mir-125b. Hepatology, in press.
11. Shen J, Wang S, Zhang YJ, et al. Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology 2012; 55: 1799-808.
12. Shen J, Wang S, Zhang YJ, et al. Genome-wide aberrant DNA methylation of microRNA host genes in hepatocellular carcinoma. Epigenetics 2012; 7: 1230-7.
13. Brakensiek K, Wingen LU, Länger F, et al. Quantitative high-resolution CpG island mapping with Pyrosequencing reveals disease-specific methylation patterns of the CDKN2B gene in myelodysplastic syndrome and myeloid leukemia. Clin Chem 2007; 53: 17-23.
14. Potapova A, Albat C, Hasemeier B, et al. Systematic cross-validation of 454 sequencing and pyrosequencing for the exact quantification of DNA methylation patterns with single CpG resolution. BMC Biotechnol 2011; 11: 6.
15. Huss S, Nehles J, Binot E, et al. beta-Catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis. Histopathology, in press.
16. Christgen M, Noskowicz M, Schipper E, et al. Oncogenic PIK3CA mutations in lobular breast cancer progression. Genes Chromosom Cancer 2013; 52: 69-80.
17. Takai D, Jones PA,. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A 2002; 99: 3740-5.
18. Elkon R, Linhart C, Sharan R, et al. Genome-wide in silico identification of transcriptional regulators controlling the cell cycle in human cells. Genome Res 2003; 13: 773-80.
19. Xiong Z, Laird PW,. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997; 25: 2532-4.
20. Hennessey PT, Ochs MF, Mydlarz WW, et al. Promoter methylation in head and neck squamous cell carcinoma cell lines is significantly different than methylation in primary tumors and xenografts. PLoS One 2011; 6: e20584.
21. Brakensiek K, Langer F, Kreipe H, et al. Low level of DAP-kinase DNA methylation in myelodysplastic syndrome. Blood 2004; 104: 1586-88.
22. Lehmann U, Berg-Ribbe I, Wingen LU, et al. Distinct methylation patterns of benign and malignant liver tumors revealed by quantitative methylation profiling. Clin Cancer Res 2005; 11: 3654-60.
23. Claus R, Wilop S, Hielscher T, et al. A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR. Epigenetics 2012; 7: 772-80.
24. Stoot JH, Coelen RJ, De Jong MC, et al. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford) 2010; 12: 509-22.
25. Nahm CB, Ng K, Lockie P, et al. Focal nodular hyperplasia-a review of myths and truths. J Gastrointest Surg 2011; 15: 2275-83.
26. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic ACids Res 2005; 33: e179.
27. Andersen JB, Factor VM, Marquardt JU, et al. An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Science Trans Med 2010; 2: 54ra77.
28. Yang JD, Seol SY, Leem SH, et al. Genes associated with recurrence of hepatocellular carcinoma: integrated analysis by gene expression and methylation profiling. J Korean Med Sci 2011; 26: 1428-38.
29. Tao R, Li J, Xin J, et al. Methylation profile of single hepatocytes derived from hepatitis B virus-related hepatocellular carcinoma. PLoS One 2011; 6: e19862.
30. Ammerpohl O, Pratschke J, Schafmayer C, et al. Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 2012; 130: 1319-28.
31. Neumann O, Kesselmeier M, Geffers R, et al. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. Hepatology 2012; 56: 1817-27.
32. Lehmann U, Hasemeier B, Christgen M, et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 2008; 214: 17-24.
33. Cekaite L, Rantala JK, Bruun J, et al. MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia 2012; 14: 868-79.
34. Selcuklu SD, Donoghue MT, Rehmet K, et al. MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells. J Biol Chem 2012; 287: 29516-28.
35. Zhang H, Qi M, Li S, et al. microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. Mol Cancer Ther 2012; 11: 1454-66.
36. Trankenschuh W, Puls F, Christgen M, et al. Frequent and distinct aberrations of DNA methylation patterns in fibrolamellar carcinoma of the liver. PLoS One 2010; 5: e13688.
37. Capel E, Flejou JF, Hamelin R,. Assessment of MLH1 promoter methylation in relation to gene expression requires specific analysis. Oncogene 2007; 26: 7596-600.
38. van Vlodrop IJ, Niessen HE, Derks S, et al. Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin Cancer Res 2011; 17: 4225-31.
39. Lehmann U, Langer F, Feist H, et al. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002; 160: 605-12.
40. Claus R, Hackanson B, Poetsch AR, et al. Quantitative analyses of DAPK1 methylation in AML and MDS. Int J Cancer 2012; 131: E138-42.
41. Bandres E, Agirre X, Bitarte N, et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 2009; 125: 2737-43.
42. Huang YW, Liu JC, Deatherage DE, et al. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res 2009; 69: 9038-46.
43. Tsai KW, Wu CW, Hu LY, et al. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int J Cancer 2011; 129: 2600-10.
44. Yan H, Choi AJ, Lee BH, et al. Identification and functional analysis of epigenetically silenced microRNAs in colorectal cancer cells. PLoS One 2011; 6: e20628.
45. Lodygin D, Tarasov V, Epanchintsev A, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008; 7: 2591-600.